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Abstract Eosinophilic granulomatosis with polyangiitis
(EGPA), previously called Churg–Strauss syndrome, fre-
quently affects the peripheral nervous system. We con-
ducted a multicenter, double-blind, three-arm treatment
period, randomized, pre-post trial to assess the efficacy of
intravenous immunoglobulin (IVIg) administration for
residual peripheral neuropathy in patients with EGPA that
is in remission, indicated by laboratory indices. Twenty-
three patients were randomly assigned into three groups,
in which the timing of IVIg and placebo administration
was different. Each group received one course of inter-
vention and two courses of placebo at 2-week intervals.
Treatment effects were assessed every 2 weeks for
8 weeks. The primary outcome measure, the amount of
change in the manual muscle testing sum score 2 weeks
after IVIg administration, significantly increased
(p = 0.002). The results over time suggested that this
effect continued until the last assessment was done
8 weeks later. The number of muscles with manual mus-
cle testing scores of three or less (p = 0.004) and the
neuropathic pain scores represented by the visual ana-
logue scale (p = 0.005) also improved significantly
2 weeks after IVIg administration. This study indicates
that IVIg treatment for EGPA patients with residual
peripheral neuropathy should be considered even when
laboratory indices suggest remission of the disease.
Keywords Churg–Strauss syndrome  Eosinophilic
granulomatosis with polyangiitis  Intravenous
immunoglobulin  Neuropathy  Treatment
Introduction
Peripheral neuropathy is caused by primary and secondary
vasculitides of various etiologies [1, 2]. Eosinophilic
granulomatosis with polyangiitis (EGPA), previously
called as Churg–Strauss syndrome, frequently involves the
peripheral nervous system [3–5]. As opposed to involve-
ment of the heart, lungs, gastrointestinal tract, kidneys, or
central nervous system, which can be life threatening,
peripheral neuropathy caused by vasculitis alone does not
significantly affect patient survival [2, 6]. However,
peripheral neuropathy can significantly disrupt day-to-day
functioning and quality of life of patients because of
weakness or pain in the extremities [7, 8]. Administration
of corticosteroids alone or a combination of corticosteroids
and immunosuppressive agents such as cyclophosphamide
typically achieves remission and results in good survival
rates in patients with EGPA [9–11]; however, patients may
suffer from chronic residual functional deficits caused by
neuropathy even after remission has been achieved [8, 12,
13]. Although such deficits may disrupt the day-to-day
functioning and quality of life of patients, studies to target
the residual neuropathy are still scarce.
Members of the Research Group for IVIg for EGPA/CSS in Japan are
presented in Appendix section.
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In this article, we assessed the efficacy of intravenous
immunoglobulin (IVIg) for EGPA from the viewpoint of




A multicenter, double-blind, 3-arm treatment period, ran-
domized, pre-post trial was done at 23 hospitals (Fig. 1). As
this disease is relatively rare, we adopted this design rather
than a placebo-controlled, parallel-group trial. Patients who
fulfilled the following criteria were included in the study: (1)
a diagnosis of EGPA [14–16]; (2) aged between 20 and
74 years; (3) manifestation of weakness of both less than
three with manual muscle testing (MMT) [17] in more than
one muscle and MMT sum score of less than 130 as
described below; and (4) disease remission induced by more
than 4 weeks of steroid treatment. Steroid treatment was
defined as the use of more than 40 mg/day of prednisolone
(or an equivalent dosage of another steroid) in the initial
phase, followed by a reduction of dosage and a subsequent
maintenance therapy of 5–20 mg/day of prednisolone (or an
equivalent dosage of another steroid) for more than 4 weeks.
A diagnosis of EGPA was based on the 2012 revised Inter-
national Chapel Hill Consensus Conference Nomenclature
and the diagnostic criteria of the Ministry of Health and
Welfare of Japan for definite EGPA (1998) [14–16]. All
patients had asthma, eosinophilia, and multiple mononeu-
ropathy. Patients also showed histological findings consistent
with EGPA and/or a characteristic clinical course [14, 15].
MMT was assessed at 30 points for each patient by
neurologists, and scored as: 5, normal; 4, good; 3, fair; 2,
poor; 1, trace; and 0, zero [17]. The following movements
(and their associated muscles) were examined bilaterally:
elbow flexion at antebrachial supination (biceps brachii),
elbow extension (triceps brachii), elbow flexion at ante-
brachial mid-position (brachioradialis), wrist flexion
(flexor carpi radialis and flexor carpi ulnaris), wrist
extension (extensor carpi radialis longus, extensor carpi
radialis brevis, and extensor carpi ulnaris), extension of
metacarpophalangeal joint of thumb (extensor pollicis
longus and extensor pollicis brevis), opposition of thumb
(opponens pollicis), abduction of fingers (interossei dor-
sales), and adduction of fingers (interossei palmares) in the
upper extremities, and knee flexion (hamstring), knee
extension (quadriceps), ankle plantar flexion (gastrocne-
mius and soleus), ankle inversion (tibialis posterior), ankle
dorsiflexion (tibialis anterior), and ankle eversion (peron-
eus longus and peroneus brevis) in the lower limbs.
Because the strengths of muscles that cause extension of
the metacarpophalangeal joint of the thumb, abduction of
the fingers, and adduction of the fingers were fine, we set
the highest scores of these points to four to increase the
reproducibility of the results of the assessment. Therefore,
the full score of the sum of MMTs was 144.
Exclusion criteria were: history of allergy or shock to
IVIg; IgA deficiency; severe renal failure defined as serum
blood urea nitrogen levels no less than 40 mg/dl or serum
creatinine levels no less than 4 mg/dl; history of cerebro-
vascular or cardiovascular disease; high risk of thrombosis;
hemolytic or hemorrhagic anemia; congestive heart failure
of NYHA functional class III or worse; immunodeficiency
inappropriate to enroll in this study; severe muscle weak-
ness; pregnancy or breast feeding; previous participation in
a Phase II trial; improvement of more than 10 % on MMT
sum score during 4-week pretreatment period; participation
in other clinical trials within the 12 weeks prior to giving
informed consent; and ineligibility for enrollment judged
by physicians-in-charge.
Fig. 1 Treatment and observation schedule. Patients were randomly
assigned into three groups (groups A, B, and C), in which the timing
of intravenous immunoglobulin (IVIg) and placebo administration
was different. Each group received one course of IVIg and two
courses of placebo at 2-week intervals. IVIg was administered during
the first course for group A, the second course for group B, and the
third course for group C. Medical examinations were done on a
2-week interval schedule starting from 4 weeks before the first
infusion to 8 weeks after the start of the third course
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This study is registered in the JAPIC clinical trials
registry, number JapicCTI-060242(ja)(en). Patients pro-
vided written informed consent before enrolment. The
protocol was approved by the institutional review board at
each participating center. The study was done in accor-
dance with the Declaration of Helsinki and good clinical
practice.
Randomization and masking
Patients were randomly assigned into three groups (groups
A, B, and C), in which the timing of IVIg (freeze-dried
sulfonated human normal immunoglobulin, 0.4 g/kg for
five consecutive days) and placebo (0.9 % isotonic sodium
chloride solution) administration was different. Each group
received one course of IVIg and two courses of placebo at
2-week intervals. IVIg was administered during the first
course for group A, the second course for group B, and the
third course for group C. This 3-arm design better ensures
blindness compared to a 2-arm design. Patients were
assigned to a computer-generated randomization list.
Patients and investigators were masked to treatment
allocation. Vials and drip chambers were covered and
opaque routes were adopted for both IVIg and placebo to
maintain blindness of the study drug for patients and
investigators. Surgical tape was put on the drip chambers
so that the liquid surface was not visible. A trusted third
party verified the blindness. In addition, preparation and
cleanup of the drugs were done by a person in charge who
was unrelated to the patients or the investigators.
The drug codes were broken and made available for data
analysis when the study was completed and the data files
had been verified.
Procedures
The same volume and infusion rate were used for IVIg and
placebo administration. Medical examinations were done
on a 2-week interval schedule starting from 4 weeks before
the first infusion to 8 weeks after the start of the third
course. The medical examination was performed immedi-
ately before the infusion, when they overlapped. Blood and
urine samples were obtained for the screening of general
conditions at 4 weeks prior to the experiment, immediately
before the first infusion, and at 2-week intervals thereafter,
until 8 weeks after the start of the third course. Consecutive
neurological examinations were performed by one neurol-
ogist for each patient during the study.
The primary outcome measure was the amount of
change in the MMT sum score 2 weeks after IVIg
administration. The secondary measures were changes in
the number of muscles with an MMT score of 3 or less,
visual analogue scale (VAS) scores [18], and a modified
Barthel index [19] two weeks after IVIg administration.
Changes in vibratory sensation in the distal portions of the
lower limbs and deep tendon reflexes also were assessed.
Nerve conduction studies were performed using standard
methods. Hematological examinations were assessed by
the items shown in Table 1. Urinary protein and sugar were
also assessed. These indices were assessed before IVIg/
placebo and every 2 weeks thereafter. Electrocardiography
was performed at baseline and at 6 and 12 weeks after the
start of the first course. The results of total protein and IgG
levels that may increase after IVIg administration were
blinded for examiners.
Statistical analysis
Quantitative data were presented as the mean ± standard
deviation (SD). To assess the demographic features of
patients, the v2 test, Fisher’s exact test, and one-way ana-
lysis of variance (ANOVA) were used as appropriate. The
primary and secondary endpoints for change after IVIg
administration were assessed by the use of a paired t test.
For comparison of the secondary endpoints with placebo,
we used a two-sample t test and a one-way ANOVA to
calculate the differences between the groups. Two-sided
p values less than 0.05 were deemed statistically signifi-
cant. Statistical analyses were done using SAS (version
9.1.3).
Results
A total of 23 patients were assigned into groups A to C
(eight patients for group A, eight patients for group B, and
seven patients for group C). All patients were assessed as
an analysis object. The demographics and characteristics
assessed before IVIg/placebo administration were not sig-
nificantly different among the three groups (Table 1).
Disease activity indicated by eosinophil count, C-reactive
protein, IgE, and myeloperoxidase-antineutrophil cyto-
plasmic antibodies (ANCA) were within the normal range,
except for a slight elevation of IgE levels in five, three, and
two patients of the groups A, B, and C, respectively. The
findings from electrocardiography were unremarkable in
all patients. In addition to muscle weakness, all patients
manifested sensory deficits. The presence of neuropathy
was confirmed by a reduction or absence of deep tendon
reflexes in the affected limbs and/or abnormalities in nerve
conduction indices. Pathological reflexes were absent in all
patients.
Sequential changes in clinical scores are summarized in
Tables 2 and 3. The primary outcome measure, the amount
of change in the MMT sum score 2 weeks after IVIg
administration, was 7.13 ± 9.76 (p = 0.002), which was a
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Table 1 Background of patients
Parameters Group A (n = 8) Group B (n = 8) Group C (n = 7) All patients (n = 23) p values
Age 50.3 ± 17.2 61.0 ± 16.2 62.6 ± 4.5 57.7 ± 14.7 0.203
Sex (M:F) 3:5 2:6 2:5 7:16 1.000
Body weight (kg) 60.61 ± 13.58 49.80 ± 9.08 60.04 ± 9.93 56.68 ± 11.76 0.120
Duration of disease (years) 1.66 ± 1.55 0.81 ± 0.60 5.23 ± 10.78 2.45 ± 6.02 0.344
MMT sum score 110.00 ± 12.56 113.19 ± 12.57 106.29 ± 21.36 109.98 ± 15.26 0.702
Modified Barthel index 87.1 ± 15.2 79.5 ± 27.4 78.1 ± 7.3 81.7 ± 18.5 0.612
Visual analogue scale 64.75 ± 32.19 80.75 ± 20.25 61.86 ± 28.84 69.43 ± 27.56 0.365
Laboratory findings
White blood cell (no./mm3) 8,275 ± 2,468 6,888 ± 1,063 8,186 ± 1,981 7,765 ± 1,949 0.300
Eosinophil (no./mm3) 55.0 ± 45.0 127.3 ± 98.0 251.5 ± 331.7 140.0 ± 200.9 0.165
Hemoglobin (g/dl) 14.00 ± 1.94 12.61 ± 1.61 13.96 ± 1.85 13.50 ± 1.84 0.246
Platelet (910,000 no./mm3) 26.08 ± 4.76 22.29 ± 3.10 22.94 ± 3.01 23.80 ± 3.96 0.125
Aspartate transaminase (IU/L) 16.1 ± 3.1 18.8 ± 7.8 19.6 ± 3.2 18.1 ± 5.3 0.426
Alanine transaminase (IU/L) 17.9 ± 9.3 24.4 ± 30.3 21.7 ± 7.9 21.3 ± 18.6 0.796
Lactate dehydrogenase (IU/L) 208.9 ± 53.7 204.0 ± 38.3 230.1 ± 28.3 213.7 ± 41.6 0.461
Blood urea nitrogen (mg/dL) 12.03 ± 4.33 14.58 ± 4.37 15.33 ± 5.61 13.92 ± 4.76 0.380
Creatinine (mg/dL) 0.613 ± 0.163 0.585 ± 0.104 0.733 ± 0.202 0.640 ± 0.165 0.194
C-reactive protein (mg/dL) 0.051 ± 0.055 0.110 ± 0.092 0.094 ± 0.105 0.085 ± 0.086 0.385
Thrombomodulin (FU/mL) 2.86 ± 0.69 3.09 ± 0.67 3.46 ± 0.55 3.12 ± 0.66 0.222
IgG (mg/dL) 817.1 ± 191.8 892.9 ± 200.1 840.9 ± 343.5 850.7 ± 240.2 0.827
IgE (IU/mL) 202.88 ± 109.52 254.98 ± 335.70 113.66 ± 128.27 193.84 ± 218.17 0.473
MPO-ANCAa
Positive/negativeb 4/4 0/8 2/5 6/17 0.069
Daily amount of prednisolone at entry (mg/day) 15.75 ± 5.53 13.44 ± 6.40 14.00 ± 5.84 14.41 ± 5.75 0.724
Use of immunosuppressants 2 cases (25.0 %) 3 cases (37.5 %) 2 cases (28.6 %) 7 cases (30.4 %) 1.000
MMT manual muscle testing, MPO-ANCA myeloperoxidase-antineutrophil cytoplasmic antibodies
a Assessed at the time of diagnosis. MPO-ANCA was negative in all cases at the time of entry
b Negative value was defined as less than 10 EU
Table 2 Sequential changes in MMT sum scores after intravenous immunoglobulin administration
a. Baselinea b. 2 weeks c. 4 weeks d. 6 weeks e. 8 weeks p values*
b–a c–a d–a e–a
MMT sum scores and the change in MMT sum scores
Group A
(n = 8)
110.00 ± 12.56 118.13 ± 11.15 122.75 ± 9.99 123.81 ± 10.16 124.50 ± 9.07 0.046 0.015 0.016 0.011
– 8.13 ± 9.49 12.75 ± 11.29 13.81 ± 12.44 14.50 ± 11.87
Group B
(n = 8)
117.19 ± 11.50 123.00 ± 13.20 128.06 ± 13.05 127.81 ± 11.40 128.63 ± 11.21 0.022 0.019 0.014 0.006
– 5.81 ± 5.62 10.88 ± 10.12 10.63 ± 9.24 11.44 ± 8.36
Group C
(n = 7)
112.86 ± 23.83 120.36 ± 12.49 123.50 ± 10.22 124.36 ± 9.99 128.07 ± 8.01 0.214 0.151 0.125 0.059
– 7.50 ± 14.26 10.64 ± 17.12 11.50 ± 17.09 15.21 ± 17.29
All patients
(n = 23)
113.37 ± 16.02 120.50 ± 11.91 124.83 ± 10.97 125.37 ± 10.23 127.02 ± 9.34 0.002 \0.001 \0.001 \0.001
– 7.13 ± 9.76b 11.46 ± 12.41 12.00 ± 12.57 13.65 ± 12.30
MMT manual muscle testing
* Paired t test for change from baseline
a Baseline scores were those immediately before intravenous immunoglobulin administration
b Primary endpoint
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significant increase compared to the baseline score
(113.37 ± 16.02–120.50 ± 11.91) (Table 2). Significantly
increased scores (p \ 0.001), compared to pretreatment
scores, were also observed 4 weeks (124.83 ± 10.97),
6 weeks (125.37 ± 10.23), and 8 weeks (127.02 ± 9.34)
later.
As for the secondary measures, the change in the
number of muscles with MMT scores of 3 or less 2 weeks
after IVIg administration was -2.7 ± 4.0 (p = 0.004),
which was a significant reduction compared to the baseline
score (9.8 ± 6.8–7.2 ± 5.0) (Table 3). Significantly
reduced scores, compared to pretreatment scores, were also
observed at 4 weeks (5.7 ± 4.6, D (the amount of change
from baseline) = -4.1 ± 5.6, p = 0.002), 6 weeks
(5.6 ± 4.3, D = -4.3 ± 5.2, p = 0.001), and 8 weeks
later (4.9 ± 3.3, D = -5.0 ± 5.6, p \ 0.001). The amount
of change in the VAS 2 weeks after IVIg administration
was -4.96 ± 7.72 (p = 0.005), which was a significant
reduction from the baseline score (67.61 ± 28.40–62.65
± 28.23). Significantly reduced scores, compared to pre-
treatment scores, were also observed at 4 weeks (59.57 ±
29.98, D = -8.04 ± 10.93, p = 0.002), 6 weeks (60.39 ±
26.98, D = -7.22 ± 10.71, p = 0.004), and 8 weeks
(59.59 ± 28.92, D = -8.02 ± 15.42, p = 0.021). On the
contrary, the modified Barthel index was not significantly
reduced (84.3 ± 18.6 for pretreatment and 86.8 ± 16.7,
89.4 ± 16.0, 90.2 ± 13.7, and 90.8 ± 13.3, respectively,
for 2, 4, 6, and 8 weeks after treatment).
The effect of IVIg was compared to that of placebo
during the first course of infusion (Table 4). Patients in
group A (n = 8), who were administered IVIg, showed a
significantly greater reduction in the number of muscles
with MMT scores of three or less than those in groups B
and C (n = 15), who received placebo (-4.0 ± 5.3 versus
-0.5 ± 1.6, p = 0.028). Significant differences were not
found between IVIg and placebo in the items of the indices
of MMT sum score (8.13 ± 9.49 versus 3.13 ± 3.52),
reduction of VAS (-5.00 ± 8.62 versus -5.13 ± 7.44),
and increase of modified Barthel index (2.4 ± 4.3 versus
1.9 ± 5.7).
Changes in the primary and secondary outcome mea-
sures after IVIg administration were not significantly
associated with age, sex, body weight, duration of disease,
or use of adjunctive immunosuppressants.
Adverse events—judged by the investigator—related to
the study medication were reported in 14 patients (61 %).
These included headache (4 events), elevation of alanine
aminotransferase (3 events), lassitude (2 events), erythema
(1 event), purpura (1 event), chest pain (1 event), itching at
the site of infusion (1 event), swelling at the site of infusion
(1 event), edema in the limbs (1 event), fever (1 event),
elevation of aspartate aminotransferase (1 event), elevation
of c-glutamyl transpeptidase (1 event), elevation of lactate
dehydrogenase (1 event), reduced platelet count (1 event),
and reduced white blood cell count(1 event). All of them
were mild or moderate and most of them spontaneously
Table 3 Sequential changes in secondary clinical scores after intravenous immunoglobulin administration
a. Baselinea b. 2 weeks c. 4 weeks d. 6 weeks e. 8 weeks p values*
b–a c–a d–a e–a
Number of muscles with MMT scores of three or less
Group A (n = 8) 11.0 ± 6.1 7.0 ± 4.4 5.5 ± 4.3 5.3 ± 3.8 5.1 ± 3.3
Group B (n = 8) 7.8 ± 4.8 6.0 ± 4.6 4.1 ± 4.0 4.3 ± 3.8 4.3 ± 3.8
Group C (n = 7) 10.9 ± 9.4 8.7 ± 6.2 7.9 ± 5.2 7.4 ± 5.3 5.3 ± 3.2
All patients (n = 23) 9.8 ± 6.8 7.2 ± 5.0 5.7 ± 4.6 5.6 ± 4.3 4.9 ± 3.3 0.004 0.002 0.001 \0.001
Visual analogue scale
Group A (n = 8) 64.75 ± 32.19 59.75 ± 33.72 59.13 ± 30.43 57.00 ± 29.75 55.50 ± 33.55
Group B (n = 8) 77.63 ± 21.49 71.13 ± 21.75 68.63 ± 26.28 70.00 ± 23.72 70.81 ± 24.28
Group C (n = 7) 59.43 ± 31.41 56.29 ± 29.83 49.71 ± 34.44 53.29 ± 28.00 51.43 ± 28.26
All patients (n = 23) 67.61 ± 28.40 62.65 ± 28.23 59.57 ± 29.98 60.39 ± 26.98 59.59 ± 28.92 0.005 0.002 0.004 0.021
Modified Barthel index
Group A (n = 8) 87.1 ± 15.2 89.5 ± 11.2 92.1 ± 8.0 92.3 ± 7.9 93.4 ± 6.9
Group B (n = 8) 80.0 ± 26.9 84.5 ± 25.3 85.1 ± 25.6 87.3 ± 21.4 87.4 ± 21.2
Group C (n = 7) 85.9 ± 10.7 86.4 ± 10.8 91.1 ± 8.0 91.1 ± 8.0 91.9 ± 6.8
All patients (n = 23) 84.3 ± 18.6 86.8 ± 16.7 89.4 ± 16.0 90.2 ± 13.7 90.8 ± 13.3 0.107 0.020 0.009 0.005
MMT manual muscle testing
* Paired t test for change from baseline
a Baseline scores were those immediately before intravenous immunoglobulin administration
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resolved. As for the serious adverse events, one patient
suffered from pneumonia and another had a urinary tract
infection. The former was considered to be related to the
administration of steroids, and the latter appeared tran-
siently 4 weeks after the administration of IVIg; therefore,
these events were considered to be unrelated to IVIg
administration.
Discussion
Although a successful treatment strategy for the acute
phase of EGPA has been established [9–11, 20], some
patients show persistent disease activity in spite of treat-
ment [9, 20]. In EGPA, cardiac, gastrointestinal, and renal
involvement, especially the first one, may become the
cause of death [3, 5, 21], and cardiac involvement signif-
icantly affects the mortality rate [5]. In a previous retro-
spective study of 28 patients with neuropathy due to EGPA
who were diagnosed by sural nerve biopsy, the patients
who responded well to the initial 4-week corticosteroid
therapy regained self-controlled functional status in a long-
term follow-up (determined by modified Rankin scale),
whereas those that did not respond well to the initial cor-
ticosteroid therapy were more likely to lead a dependent
existence [12]. Peripheral nerve involvement influences the
ability of patients to perform the activities of daily living
[8, 12]. That study indicated that residual neuropathy might
exist even after laboratory indices had suggested that
remission had been achieved. Therefore, a treatment
strategy to improve residual neuropathy is needed even
when the activity of the disease, as indicated by laboratory
indices, is negative. Previous studies concerning treatments
for vasculitides have mainly focused on improvements in
laboratory indices or on survival rate. This is the first study
to focus on improvements in functional deficits that remain
in spite of laboratory indices indicating remission.
In this study, we elucidated the efficacy of IVIg for
improving the residual neuropathy of patients with EGPA
during disease remission indicated by laboratory indices
after initial immunosuppressive treatment. The results of
the MMT sum score as well as individual MMT scores of
three or less over time suggested that the effects of IVIg
continued during the 8-week follow-up period. As this
disease is relatively rare, we adopted a study design to
compare the amount of change in the MMT sum score
before and after the treatment rather than a placebo-con-
trolled, parallel-group trial. However, sub-analyses also
revealed significantly better outcomes compared to placebo
in the number of muscles with an MMT score of 3 or less.
The scale of pain (i.e. VAS), which may significantly affect
quality of life, was also significantly improved after
treatment.
It has been suggested that IVIg treatment is effective for
patients with small-to-medium vessel vasculitis, especially
when disease activity persists after standard therapy [22].
As for EGPA, scores on the modified Rankin scale sig-
nificantly improved after a combination therapy of plas-
mapheresis and IVIg in patients receiving both prednisone
and cyclophosphamide [23]. However, unlike our patients,
the patients included in that study still manifested abnormal
laboratory indices including positive ANCA titers and
C-reactive proteins at baseline [23].
The mechanisms by which IVIg improves the functional
status of patients with EGPA have not yet been elucidated.
The efficacy of IVIg for neuropathy has been reported in
patients with Guillain–Barre´ syndrome [24], chronic
inflammatory demyelinating polyneuropathy [25], painful
neuropathy associated with Sjo¨gren’s syndrome [26], and a
subgroup of diabetic neuropathy [27]. A variety of mech-
anisms have been thought to be responsible for the effect of
IVIg on neuropathy, including neutralization of autoanti-
bodies, inhibition of complement pathways, alteration of
Fc receptor expression, and alteration of cytokine profiles
Table 4 Comparison between
IVIg and placebo after the first
course of administration
MMT manual muscle testing, CI
confidence interval
Change from the baseline Difference (95 % CI) p values
MMT sum score
IVIg (group A, n = 8) 8.13 ± 9.49 4.99 (-0.64, 10.63) 0.080
Placebo (groups B and C, n = 15) 3.13 ± 3.52
Number of muscles with MMT scores of three or less
IVIg (group A, n = 8) -4.0 ± 5.3 -3.5 (-6.5, -0.4) 0.028
Placebo (groups B and C, n = 15) -0.5 ± 1.6
Visual analogue scale
IVIg (group A, n = 8) -5.00 ± 8.62 0.13 (-7.02, 7.28) 0.969
Placebo (groups B and C, n = 15) -5.13 ± 7.44
Modified Barthel index
IVIg (group A, n = 8) 2.4 ± 4.3 0.5 (-4.3, 5.3) 0.827
Placebo (groups B and C, n = 15) 1.9 ± 5.7
J Neurol (2015) 262:752–759 757
123
[28]. It is presumed that the specific action of IVIg varies
depending on the underlying pathogenesis of a given dis-
ease. In EGPA, IVIg might control smoldering inflamma-
tion in the peripheral nervous system.
In our study, disease activity indicated by laboratory
indices was negative in all patients. It is notable that the
improvement of neurological deficits was observed even in
patients considered classically as being in remission.
Therefore, this study indicates that IVIg treatment for
patients with residual neuropathy should be considered
even when laboratory indices suggest remission of the
disease. Differential clinical profiles between patients with
and without ANCA have been reported [4]. Another study
revealed that serum IgG4 levels are markedly elevated in
active EGPA and correlate with the number of organ
manifestations and disease activity [29]. These findings
may suggest a participation of some peculiar mechanisms
other than ANCA-related pathways in the pathogenesis of
EGPA. Such unraveled mechanisms might induce smol-
dering disease activity, which could not be measured by
conventional laboratory indices. Further studies are needed
to elucidate the mechanisms underlying the efficacy of
IVIg for EGPA.
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